Monday, 13 January 2020

Verrucous Carcinoma Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Global Verrucous Carcinoma Market Research Report, by Diagnosis (Biopsy, Endoscopy, Imaging Tests), Treatment (Radiation Therapy, Chemotherapy), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Global Forecast Till 2023
Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest share in the global Verrucous Carcinoma market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
Posted by at No comments:

Healthcare Asset Management Market to Observe Strong Development by 2019

Healthcare Asset Management Market: Information, Product (Radiofrequency Identification (RFID) Devices, and Others), Application (Hospital Asset Management and Others), End-User (Hospital, Laboratory, Pharmaceutical, and Others)–Global Forecast Till 2023
Market Scenario
The healthcare asset management market to showcase an extraordinary 18.2% CAGR over the forecast period (2018-2023), revealed Market Research Future (MRFR) in a well-outlined report on the same market.
The healthcare asset management includes patient record management, easy access to maintenance record, locating medical equipment, and registering of the status of each equipment. Increasing demand for healthcare and the availability of varying types of treatment are creating a situation where easy access to everything is prized. This would help in quick and efficient service delivery to patients. When time is of the essence, then keeping everything at a hand’s distance becomes necessary. Healthcare asset management does that quite efficiently. MRFR, while having a detailed study of the healthcare asset management market, harps on segments and their volume-wise and value-wise valuation. In sync, it also analyses the factors that may play an important role in the coming years.
Patient safety gets the priority in the healthcare sector which can provide the much-needed traction to the market. Among the other factors, its ability to simplify the work process can be considered one of the major influencers. In addition, with rising investment in R & D, the sector is only going to flourish. However, accuracy issues and high installation cost can hamper the expected growth rate of the market.
Key Players
  • cenTrak,
  • Airista Flow,
  • GE Healthcare,
  • IBM Corporation,
  • Infor Inc.,
  • Tyco Security Products.,
  • Intelligent InSites,
  • Motorola Solutions, Inc.,
  • Radianse, JADAK (a Novanta Company),
  • Siemens Healthineers, Sonitor Technologies,
  • Stanley Black & Decker, Inc.,
  • Ekahau, Inc.
Segmentation
The healthcare asset management market has been segmented on the basis of product, application, and end-user.
On the basis of product, the market has been classified as real-time location systems (RTLS), radiofrequency identification (RFID) devices and ultrasound & infrared tags. The real-time location systems (RTLS) segment has been further divided into hardware, software and services. The hardware segment has been further divided into tags/badges and readers/interrogators.
The radiofrequency identification (RFID) devices have been classified as hardware, and software and services. the hardware segment has been divided tags, readers/interrogators, and accessories. The tags sub-segment has been segmented into passive tags and active tags. The passive tags segment has been divided into high-frequency (HF) tags, ultra-high-frequency (UHF) tags and low-frequency (LF) tags. Furthermore, the application segment has been sub-segmented into hospital asset management and pharmaceutical asset management. The hospital asset management segment includes equipment tracking and management, patient management, temperature and humidity monitoring, staff management and infection control and hand hygiene compliance. The pharmaceutical asset management segment includes drug anti-counterfeiting and supply chain management.
The market, by end-user, has been segmented into Hospital/Clinic, Laboratories, Pharmaceutical companies, Biotechnology.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The healthcare asset management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The healthcare asset management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The healthcare asset management market in the Middle East & Africa has been segmented into the Middle East and Africa.
The European healthcare asset management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
Regional Summary
MRFR included regions such as the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) in their report on the healthcare asset management market.
The Americas is a market that is highly evolved, both infrastructurally and technologically. High investment potential in the region enables various end-users in integrating the healthcare asset management market. These factors are going to play a big role in maintaining the premier position it is enjoying now in the global market.
Europe’s market is the second biggest one where the crisis of counterfeit drugs can be avoided with such effective methods. At the same time, the increasing investment for research and development sector can assure the market of better management technology in the coming years. The regional healthcare sector is relying much on the prosperity of healthcare asset management as it can ease the entire workflow to back the growing demands from patients. The AAPC market is all set to grow with the fastest CAGR during the forecast period. Rapid digitization in the healthcare sector is expected to boost the market. The MEA market can contribute a small part only as the region is technologically not that well-structured.
Browse more Healthcare IT Reports @
Posted by at No comments:
Labels:

Bone Implant Market Dynamics, Forecast, Analysis and Supply Demand 2019

“Bone Implant Market” Exclusive Analysis by  Future  by Biomaterial (Metal and Others), Product (Orthopedic Screws, Orthopedic Plates, and Others), Application (Hip Orthopedic Implants and Others), Device (External and Internal), and End-User–Global Forecast Till 2023
Market Scenario:
Bone implants are used to heal bone fractures or as fillers and scaffolds to facilitate the bone formation. Bone implants are surgically placed into the body and designed to restore the function by replacing or reinforcing a damaged structure. The rapid growth in aged population, increasing number of orthopedic surgeries, and rising occurrences of sports-related injuries are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by top players such as new product launches are contributing to the growth of the market. For instance, in May 2018, NN Inc. acquired Paragon Medical for USD 375 million. Paragon Medical is a medical device manufacturer which focuses on orthopedics, case and tray, and implant and instrument markets.  The acquisition supports NNs Inc.’s strategy to grow its life science revenue and positions NN Inc. as one of the ten largest contract manufacturers in orthopedics.
The rising cost of orthopedic surgeries, the high price of bone implant products, corrosion and instability of bioimplants, and stringent government policies may hinder the growth of the market during the assessment period.
The Global Bone Implant Market is expected to grow during the forecast period (2018–2023) at a CAGR ~6.8%.
Key Players
  • Depuy Synthes Inc. (Johnson & Johnson),
  • Globus Medical, Inc.,
  • NuVasive, Inc.,
  • Smith & Nephew plc. ,
  • Stryker Corporation,
  • Zimmer Biomet Holdings, Inc.,
  • Integra LifeSciences Holdings Corporation,
  • Medtronic, plc,
  • The Orthopedic Implant Company,
  • Wright Medical Group N.V.,
  • Aesculap Implant Systems,
  • BioTek Instruments, Inc.,
  • Conmed Corporation,
  • Arthrocare Corporation.
Segmentation
The global bone implant market has been segmented on the basis of biomaterial, product, application, device, and end-user.
On the basis of biomaterial, the market has been classified as metals, ceramics, and polymers. The metal segment has been further divided into titanium, stainless steel, cobalt chromium alloy, gold alloys, and Tantalum. The ceramics segment has been further divided into alumina, hydroxyapatite, beta-tricalcium, phosphate, carbon, bioglass, zirconia, and zirconia-toughened alumina. The polymers segment has been classified into polymethylmethacrylate, polytetrafluoroethylene, polyethylene, polysulfone, polyurethane, and polyether ether ketone.
The market, by products, is divided into orthopedic screws, orthopedic plates, interlocking nails (rods), and others. The market, by application, has been classified into hip orthopedic implants, knee orthopedic implants, spine orthopedic implants, dental orthopedic implants, and others.
The market, by device, is divided into external fixators and internal fixators.
The market, by end-user, has been segmented into orthopedic clinics, hospitals, and others.
Regional Market Summary
The Americas is likely to dominate the global bone implant market. The rising occurrence of osteoarthritis and osteoporosis in the aging population, increase in the number of surgical procedures, the presence of a well-established healthcare system, growing prevalence of sports injuries, and adoption of highly advanced technology are contributing to the growth of the market. According to the Annual Report of the American Joint Replacement Registry (AJRR), 860,080 hip and knee replacement procedures from 4,755 surgeons at 654 institutions were conducted in 2017.
Asia-Pacific is expected to be the fastest-growing bone implant market during the forecast period owing to the increasing prevalence of medical tourism, orthopedic diseases along with bone-related issues, and rising investments in healthcare and expansions by market players in the region. Asia-Pacific is anticipated to show significant growth from 2018 to 2023
The European market is expected to be the second-largest bone implant market. The market growth in this region can be attributed to the rising prevalence of orthopedic diseases. Moreover, the increasing demand for orthopedic implants and spinal treatment devices during the forecast period are contributing to the growth of the market in this region. Major players are adapting inorganic growth policies to expand their portfolio. For instance, Stryker Corporation, a major player in the orthopedic market acquired Vexim for USD 215 million in 2017. Vexim offers spine related products, which helped Stryker Corporation to capture the new segment.
The market in the Middle East and Africa is expected to account for the smallest share of the global bone implant market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Posted by at No comments:

Sacroiliitis Market, Segments, Growth and Value Chain 2019

Global Sacroiliitis Market Research Report, by Diagnosis (Imaging Tests and Anesthetic Injections), Treatment (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation), End-User (Hospitals, Diagnostic Centers) – Global Forecast Till 2023
Market Scenario
The Global Sacroiliitis Market is expected to witness tremendous growth during the forecast period. The growing prevalence of arthritis increase in traumatic injuries, growing prevalence of spondylitis, increased research on joint health and joint conditions, and adoption of technologically-advanced systems are the key factors for the market to grow. However, factors such as high cost of diagnostics and treatment and surgical procedures are expected to restrict the market growth during the forecast period.
According to the Centers for Disease Control and Prevention (2013to 2015), 22.7% Americans of the total population had arthritis, annually. Thus, such a high prevalence of arthritis and increasing government funding for the healthcare sector enhance the growth of this market.
However, factors such as expensive diagnostic tests and the high cost of surgical procedures are expected to restrict the market growth during the forecast period.
Key players
  • Medacta International,
  • SI-BONE,
  • Globus Medical,
  • Zyga Technology,
  • Nutech Medical,
  • CoorsTek Medical LLC,
  • Aspen Medical Products,
Segmentation
The Global Sacroiliitis Market is segmented on the basis of diagnosis, treatment, and end-user. The sacroiliitis market, by diagnosis, is sub-segmented into imaging tests and anesthetic injections. The imaging tests category includes x-ray, MRI, and CT scan. On the basis of treatment, the market is categorized into medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion, facet block, chiropractic manipulation, and physical therapy. On the basis of end-user, the market is segmented into hospitals and clinics, pharmacies, and diagnostic centers.
On the basis of region, the global sacroiliitis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Analysis
The Sacroiliitis Market is dominated by North America owing to the high prevalence of arthritis and high healthcare investments within this region. According to the Centers for Disease Control and Prevention by 2040, 78.4 million will have doctor-diagnosed arthritis.The rising adoption of technologically advanced systems for early diagnosis of diseases also drives the market growth in this region.
Asia-Pacific was projected to be the fastest growing region for the Global Sacroiliitis Market. Key factors such as the growing patient pool, the high prevalence of chronic diseases, developing healthcare infrastructure, and increasing research and development activities in the biotechnology sector influence the market in this region. The presence of major market players such as China, India, and Japan drives the market growth.
It is estimated that Europe stood second in the Global Sacroiliitis Market. The increasing prevalence of lower back disorders and the availability of minimally invasive surgical procedures for Sacroiliitis drive the market growth in this region. According to The European (2015), sacroiliac joint was the main reason for chronic low back pain in Europe.
The Middle East and Africa holds the least share of the Global Sacroiliitis Market due to the presence of stringent government policies and poor economies. However, growing awareness among the population, rising government initiatives to improve the healthcare sector, and high investments by private market players in this region can boost the market growth. 
Posted by at No comments:

Colposcopy Market Volume Forecast and Value Chain Analysis 2019

Global Colposcopy Market Research Report: Instrument Type (Optical Colposcope, Digital Colposcope), Instrument Portability (Portable, Fixed, Handheld), Application (Cancer Screening, Examinations), Magnification Type, End-User – Global Forecast Till 2023
Market Scenario
A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.
For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.
The Global Colposcopy Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.
Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.
Company Profiles            
  • Carl Zeiss
  • Olympus Corporation
  • Danaher Corporation
  • Philips Healthcare
  • CooperSurgical
  • McKesson Corporation
  • DYSIS Medical
  • Atmos
  • Alliton
  • Seliga Microscopes
  • Karl Kaps
  • Bovie Medical
Segmentation
The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.
On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.
On the basis of instrument portability, the market is classified into portable, fixed, and handheld.
On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.
On the basis of magnification type, the market is classified into fixed magnification and variable magnification
On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.
The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 
The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.
The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.
The Americas is likely to dominate the global colposcopy market owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.
Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  
The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.
Posted by at No comments:

Current and forthcoming Optical Imaging Market size in terms of volume and value 2019

Market Scenario
Optical imaging has the ability to improve point of care in the healthcare setting since it provides improved screening and detection of disease. The global optimal imaging market is anticipated to attain a valuation of USD 1.92 Bn at a CAGR of 10% over the forecast period of 2018-2023, projects Market Research Future (MRFR) in an extensive study.
Some of the Top Key Players in Optical Imaging Market are Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V. and Agfa-Gevaert N.V. etc.
Driven by critical healthcare needs, optimal imaging is gaining traction as a detector technology. Optimal imaging is a technique where cellular and molecular function in a living body is interrogated with the help of light and the special properties of photons to obtain detailed images of organs and tissues.
Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy share in the global optical imaging market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Transthyretin Amyloidosis (ATTR) Market Dynamics, Forecast, Analysis and Supply Demand 2019

Transthyretin (TTR) Amyloidosis Market Information: Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), & End-User (Ambulatory Surgical Center, Clinics) – Global Forecast Till 2023                                                                                                                          
Market Scenario
The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy share in the global Transthyretin (TTR) amyloidosis market. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)